← Leaderboards
Shaomei Wang
Cedars-Sinai Medical Center
$2,057,719
Attributed
$2,057,719
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $417.5K · FY2011–18$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,057,719 · 2
By mechanism
R01$1,576,469 · 1
R21$481,250 · 1
Top collaborators
No co-investigators on record.
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Homayon Ghiasi$23,295,165
- Anthony Bart Nesburn$4,151,152
Others in their field
Top investigators on “Subretinal Injection”
- Shannon Elizabeth Boye · University Of Florida$6,820,547
- Shaoqin - Gong · University Of Wisconsin-Madison$6,106,772
- Muna I Naash · University Of Houston$5,741,269
- David M Gamm · University Of Wisconsin-Madison$4,431,970
- Joshua L Dunaief · University Of Pennsylvania$4,041,312
- Mary Elizabeth Ruth Hartnett · University Of North Carolina Chapel Hill$3,852,766
Research focus
Subretinal InjectionPhotoreceptor DegenerationRetinalVisionRetinal DegenerationCellsPhotoreceptorsRetinaSafetyBlindnessRodent ModelAnimal ModelRepairedRattusAreaBone MarrowDoseBlood VesselsGene TherapyGeneticBaseClinicClinical TrialsChemokine
Grant awards (7)
CRISPR/Cas9 Gene Editing to Rescue Vision in Rodent Model for Autosomal Dominant Retinitis Pigmentosa$218,750
R21 · FY2018 · EY · contact PI
CRISPR/Cas9 Gene Editing to Rescue Vision in Rodent Model for Autosomal Dominant Retinitis Pigmentosa$262,500
R21 · FY2017 · EY · contact PI
Development of non-invasive cell-based therapy for retinal degeneration and assoc$1
R01 · FY2015 · EY · contact PI
Development of non-invasive cell-based therapy for retinal degeneration and assoc$409,150
R01 · FY2014 · EY · contact PI
Development of non-invasive cell-based therapy for retinal degeneration and assoc$396,625
R01 · FY2013 · EY · contact PI
Development of non-invasive cell-based therapy for retinal degeneration and assoc$417,500
R01 · FY2012 · EY · contact PI
Development of non-invasive cell-based therapy for retinal degeneration and assoc$353,193
R01 · FY2011 · EY · contact PI